Non-selective and cyclo-oxygenase-2-specific non-steroidal anti-inflammatory drugs impair the hyperaemic response of skin to brief axillary artery occlusion.
BACKGROUND
Cyclo-oxygenase-2 (COX-2)-specific inhibitors are marketed as safer analgesics than non-selective non-steroidal anti-inflammatory drugs. However, there has been conflicting evidence concerning endothelial function and cardiovascular risk after COX-2 inhibitor use. We investigated forearm skin vascular reactivity to brief axillary artery occlusion in healthy volunteers after a single dose of the non-steroidal anti-inflammatory drugs ibuprofen (non-selective) and rofecoxib (COX-2 specific).


METHODS
Ten healthy male volunteers were studied. Forearm skin blood flow was measured using laser Doppler flowmetry. Two non-invasive probes were placed on the volar surface of the forearm. The magnitude of hyperaemic response to brief (20 s) and prolonged (5 min) occlusion of the axillary artery was measured before and 2-3 h after administration of ibuprofen 800 mg or rofecoxib 25 mg. The transient hyperaemic response ratio (THRR), defined as the net peak hyperaemic flow-flux divided by the net baseline flow-flux, was calculated. Each volunteer received both drugs in random order at least 1 week apart.


RESULTS
Ibuprofen and rofecoxib increased net baseline blood flow (median (range): ibuprofen, from 23.3 (12.1-40.8) to 31.5 (17.4-77.3); rofecoxib, from 22.0 (14.6-41.0) to 29.9 (19.5-112.0); P<0.01). The net hyperaemic peak flow-flux after brief and prolonged occlusion was unchanged after both drugs. THRR was reduced by both drugs (ibuprofen, from 2.92 (2.38-3.86) to 2.09 (1.45-3.54); rofecoxib, from 3.36 (2.06-5.16) to 2.67 (1.15 -3.84); P<0.01).


CONCLUSIONS
Both COX-2 and non-selective non-steroidal anti-inflammatory drugs, when given to healthy volunteers as single therapeutic doses, decrease skin microvascular tone but do not impair maximal vasodilatory ability.
Moppett
I K
IK
University Department of Anaesthesia, Queen's Medical Centre, Nottingham NG7 2UH, UK. iain.moppett@nottingham.ac.uk
Davies
J A
JA
Mahajan
R P
RP
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001366:Axillary Artery / Q000503:physiopathology; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D005542:Forearm / Q000098:blood supply; D006801:Humans; D006940:Hyperemia / Q000503:physiopathology*; D007052:Ibuprofen / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000494:pharmacology; D017078:Laser-Doppler Flowmetry; D008297:Male; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply*; D013450:Sulfones; D014664:Vasodilation / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D007052:Ibuprofen